Merz Aesthetics® Launches Ultherapy PRIME® in the EMEA Region at the 2025 IMCAS World Congress

23.1.2025 09:00:00 CET | Business Wire | Press release

New Data is presented in the field of regenerative aesthetics

Merz Aesthetics launches Ultherapy PRIME^® in Europe, Middle East and Africa, an evolution of the non-invasive skin lifting Ultherapy^® and presents six abstracts at the 2025 International Master Course on Aging Science (IMCAS) World Congress highlighting its product portfolio and its contribution to the field of regenerative aesthetics.

“Our new Ultherapy PRIME^® device demonstrates our commitment to persist in innovation,” said Gonzalo Mibelli, EMEA President, Merz Aesthetics. “As one of the leaders in non-invasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform as a proven technology and customizable, long-lasting* treatment option.”

The focus of this year’s Merz Aesthetics Symposium at IMCAS is Regenerative Aesthetics. “Patients are looking for more sustainable ways to address aging with regenerative aesthetic treatments providing both preventive and restorative methods to improve skin health and enhance long-term confidence,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA at Merz Aesthetics. “By collaborating with experts in aesthetics and aging science, this year’s Congress enables us to showcase our advancements and leadership in this field.”

Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.

Merz Aesthetics Symposium RegenX: Elevating Skin, Lifting Confidence. – Dr. Joyce Lim, Dr. Julia Sevi, Dr. Tatjana Pavicic, Dr. Omar Haroon, Dr. Daria Voropai, Saturday, February 1, 10:30 – 12:30
Ultherapy PRIME^® Golden Lounge:
- Opening with Dr. Sabrina Fabi, Thursday, January 30, 12:30
- Expert Roundtable “Non-invasive Regenerative Biostimulation” – Dr. Tatjana Pavicic, Dr. Kerstin Ortlechner, Dr. Sonja Sattler, Thursday, January 30, 14:30
- Expert Roundtable “Importance of Visualization” – Dr. Julia Sevi, Dr. Daria Voropai, Dr. Kerstin Ortlechner, Friday, January 31, 10:00
- Expert Talk “Truly non-invasive Regenerative Collagen Biostimulation” – Dr. Tatjana Pavicic, Dr. Alec McCarthy, Friday, January 31, 12:45
IMCAS Product Analysis Session “HA Skinboosters” – Dr. Mimi Borelli, Global Medical Affairs, Merz Aesthetics, Thursday, January 30, 13:30 – 15:00
IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO, Merz Aesthetics, Friday, January 31, 16:00 – 18:00
IMCAS Product Analysis Session “Aesthetic Toxins: Pipeline & Future” – Andy Curry, PhD, Associate Medical Director, Merz Aesthetics, Saturday, February 1, 14:00 ‒ 15:30

Merz Aesthetics Booth Talks

Connecting with Confidence: Global Insights for a more patient centered approach – Dr. Shannon Humphrey, Thursday, January 30, 14:30
The power of synergy for challenging cases – Dr. Larisa Pfahl, Thursday, January 30, 15:30
Standing out in a competitive marketplace: Building an influential brand in Aesthetics – Dr. Audrey Neff, Friday, January 31, 11:00
2 is better than 1: Optimizing Results – Dr. Chris Hutton, Friday, January 31, 13:00
Synergistic strategies for décolleté treatment in mature patients – Dr. Marie-Eugénie Nichanian-Broglia, Friday, January 31, 13:30
Enhancing Skin Quality: Case study and clinical outcome – Dr. Tatiana Kuznechenkova, Friday, January 31, 15:30

E-Poster Presentations

Virtual posters will be available for viewing on-site throughout the Congress and displayed on the virtual e-poster platform with detailed abstracts.

CaHA microspheres stimulate proteoglycan expression, supporting improved skin quality and elasticity. Authors: Yoana Dimitrova, MSc; Christian Hartmann, PhD; Kristina Riegel, PhD; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl; PhD
Exploring the mode of action of elastin stimulation by CaHA microspheres. Authors: Christian Hartmann, PhD; Kristina Riegel, PhD; Yoana Dimitrova, MSc; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl, PhD
Global Perspectives on Aesthetic Treatments and Approaches for Skin Quality Improvement: Insights from an Expert Advisory Board. Authors: Martina Kerscher, MD; Kate Goldie, MD; Cyro Hirano, MD; Stephen Lowe, MD; Kavita Mariwalla, MD; Milton Moore, MD; Je Young Park, MD; Dusan Sajic, MD; Sonja Sattler, MD; Julieta Spada, MD; Vasanop Vachiramon, MD; Bianca Viscomi, MD
Microfocused Ultrasound in Regenerative Aesthetics: A Narrative Review on Mechanisms of Action and Clinical Outcomes. Authors: Vasanop Vachiramon, MD; Tatjana Pavicic, MD; Gabriela Casabona, MD; Jeremy B. Green, MD; Jennifer Levine, MD; Je Young Park, MD; Julieta Spada, MD; Mariana Muniz, MD; John Akers, PharmD; Matthew Jackson, PhD; Alec McCarthy, PhD
Arterioembolic Characteristics of Hyaluronic Acid and Calcium Hydroxylapatite Fillers within an Artificial Arterial Perfusion Model. Authors: Alec D. McCarthy, PhD; Danny J. Soares, MD; Akash Chandawarkar, MD; Julia Fedorova, MS-I; Yu Zhang, MS-I; Larry Blevins, PA-C; Alexis Bowhay, PA-C; Thomas J. Kean, PhD; David K. Funt, MD
Extracellular Matrix Response to Diluted Calcium Hydroxylapatite Microspheres and Poly-L-Latic Acid Microparticles. Authors: Gabriela Casabona, MD; Kate Goldie, MD; Niamh Corduff, MD; Alec McCarthy, PhD; Korin Leffler, PhD; Thomas Hengl, PhD; Kristina Riegel, PhD

*results can last up to a year or more, Werschler et al. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;(9)2:27-33, Ulthera Instructions For Use.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

Copyright © 2025 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera Inc. in the EU and/or certain other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250123568990/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com

Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release

Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release

CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release

A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom